EcoDrugPlus

Prostaglandin E Receptor 4 (Subtype Ep4) B

Ensembl ID : ENSPFOG00000015378
Gene Symbol: PTGER4B
1 Cross references
201 Possible Orthologues:

Prostaglandin E2 Receptor Ep1 Subtype-Like

Ensembl ID : ENSPFOG00000012794
Gene Symbol: LOC103132017
3 Cross references
165 Possible Orthologues:

Prostaglandin E2 Receptor Ep1 Subtype-Like

Ensembl ID : ENSPFOG00000000937
Gene Symbol: LOC103155000
3 Cross references
164 Possible Orthologues:

Prostaglandin E2 Receptor Ep1 Subtype-Like

Ensembl ID : ENSPFOG00000012799
Gene Symbol: LOC103131984
3 Cross references
165 Possible Orthologues:

Prostaglandin E2 Receptor Ep2 Subtype

Ensembl ID : ENSPFOG00000003007
Gene Symbol: LOC103130328
3 Cross references
202 Possible Orthologues:

Prostaglandin F Receptor

Ensembl ID : ENSPFOG00000018159
Gene Symbol: PTGFR
3 Cross references
195 Possible Orthologues:

Prostaglandin G/h Synthase 1-Like

Ensembl ID : ENSPFOG00000005446
Gene Symbol: LOC103141975
2 Cross references
212 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSPFOG00000009272
Gene Symbol: PTGIR
3 Cross references
187 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSPFOG00000001976
Gene Symbol: PTGS1
3 Cross references
182 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 2

Ensembl ID : ENSPFOG00000013808
Gene Symbol: PTGS2
3 Cross references
214 Possible Orthologues:

Proteasomal Ubiquitin Receptor Adrm1-Like

Ensembl ID : ENSPFOG00000011984
Gene Symbol: LOC103148187
4 Cross references
192 Possible Orthologues:

Proteasome 20s Subunit Alpha 1

Ensembl ID : ENSPFOG00000008506
Gene Symbol: PSMA1
1 Cross references
270 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).